Bibliothèque

Religious Minority Views on Sexual Minorities: Contemporary Ultra-Orthodox Perceptions Toward Homosexuality in Israel.

This study examined contemporary perceptions and attitudes within Israel's ultra-Orthodox (Haredi) community, a religious minority characterized by a strict interpretation of Jewish religious law, tow…

Thérapies de Conversion

Zalcberg, S., & Zalcberg-Block, S. (2025). Religious Minority Views on Sexual Minorities: Contemporary Ultra-Orthodox Perceptions Toward Homosexuality in Israel.. Arch Sex Behav, 54(10), 4259-4271. https://doi.org/10.1007/s10508-025-03316-x

01/11/2025 Lire →

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).

BACKGROUND & AIMS: It is unclear whether radiological complete response (rCR) and pathological complete response (pCR) after immune-based conversion therapy are associated with each other and with the…

Thérapies de Conversion

Yang, D. L., Yan, Y. H., Lai, Y. C., Wu, M. S., Dong, X. F., Chen, Y. Z., Li, W. F., Yang, F. Q., Yang, Y. Y., Zhong, T. M., Wang, G. D., Pang, Q. Q., Chen, K., Peng, N., Nong, J. L., Su, Z., Yu, Y. Q., Ye, L., Zeng, F. J., … GUIDANCE, i. n. v. e. s. t. i. g. a. t. o. r. s. (2025). Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).. JHEP Rep, 7(11), 101587. https://doi.org/10.1016/j.jhepr.2025.101587

01/11/2025 Lire →

[Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma].

To evaluate the efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma. This retrospecti…

Thérapies de Conversion

Lyu, K. L., Wang, M. B., Gai, C. Y., Zhang, F., Zhu, Y. G., Liu, Y., Li, J. C., Ding, W. L., Xu, S., Li, Z. H., Sun, B. K., Gao, W. D., & Tian, Z. Z. (2025). [Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma].. Zhonghua Wai Ke Za Zhi, 63(11), 1023-1030. https://doi.org/10.3760/cma.j.cn112139-20250624-00318

01/11/2025 Lire →

[Current status and prospects of minimally invasive surgical treatment for gastric cancer].

Over the past three decades years, the treatment of gastric cancer has shifted from traditional open surgery to minimally invasive surgery. Cutting-edge technologies such as three-dimensional and 4K u…

Thérapies de Conversion

Zheng, M. H., Zhang, L. Y., Ma, J. J., & Zhao, X. (2025). [Current status and prospects of minimally invasive surgical treatment for gastric cancer].. Zhonghua Wai Ke Za Zhi, 63(11), 992-997. https://doi.org/10.3760/cma.j.cn112139-20250506-00239

01/11/2025 Lire →

A bridge over troubled waters: How can we manage patients with hepatocellular carcinoma from immunotherapy to liver transplantation?

Thérapies de Conversion

Capasso, M., Giannini, E. G., & Morisco, F. (2025). A bridge over troubled waters: How can we manage patients with hepatocellular carcinoma from immunotherapy to liver transplantation?. Dig Liver Dis, 57(11), 2065-2067. https://doi.org/10.1016/j.dld.2025.08.080

01/11/2025 Lire →

Predictive factors for successful conversion therapy in gastric cancer with peritoneal metastasis: a case-control study.

BACKGROUND: Gastric cancer (GC) patients with peritoneal metastasis (PM) have a poor prognosis. Little is known about factors for successful conversion therapy in GC with PM. This study aimed to ident…

Thérapies de Conversion

Zheng, Z., & Sun, X. (2025). Predictive factors for successful conversion therapy in gastric cancer with peritoneal metastasis: a case-control study.. J Gastrointest Oncol, 16(5), 1850-1861. https://doi.org/10.21037/jgo-2025-230

31/10/2025 Lire →

Application of modified laparoscopic stomach-partitioning gastrojejunostomy for stage IV gastric cancer with gastric outlet obstruction.

Gastric outlet obstruction (GOO) is a common complication in stage IV gastric cancer, often causing malnutrition and delaying conversion therapy. Compared with conventional gastrojejunostomy (CGJ), st…

Thérapies de Conversion

Wang, H., Shao, X., Wang, P., Hu, H., Lu, Y., Jiang, Y., Li, W., Xu, Q., & Tian, Y. (2025). Application of modified laparoscopic stomach-partitioning gastrojejunostomy for stage IV gastric cancer with gastric outlet obstruction.. J Gastrointest Oncol, 16(5), 2461-2471. https://doi.org/10.21037/jgo-2025-346

31/10/2025 Lire →

Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study.

INTRODUCTION: Oesophageal cancer (EC) presents a substantial global health challenge, ranking eighth in incidence and sixth in cancer-related mortality. Oesophageal squamous cell carcinoma (ESCC) is t…

Thérapies de Conversion

Wang, C., Xie, Q., Miao, Y., He, W., Wang, K., Liu, G., Fang, Q., Peng, L., Chen, Y., Zhou, J., Lv, J., Qi, Y., Wang, Q., Shi, Q., Han, Y., & Leng, X. (2025). Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study.. BMJ Open, 15(10), e098524. https://doi.org/10.1136/bmjopen-2024-098524

21/10/2025 Lire →

Gaps in the "Rainbow Nation": A Critique of South Africa's Tolerance of Conversion Therapy.

South Africa has not yet enacted a specific legislative ban on conversion practices. This is despite widespread international consensus that so-called conversion practices-aimed at changing an individ…

Thérapies de Conversion

Baird, S. (2025). Gaps in the "Rainbow Nation": A Critique of South Africa's Tolerance of Conversion Therapy.. J Homosex, 1-28. https://doi.org/10.1080/00918369.2025.2573444

16/10/2025 Lire →

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.

In selected patients with stage IV gastric cancer, radical surgery after conversion therapy may increase survival benefit; however, there is currently no standard protocol for conversion therapy. We e…

Thérapies de Conversion

Liu, Y., Xue, Q., Wang, B., Ding, X., Zhang, R., Wang, X., Ke, B., Wang, X., Liu, N., Deng, J., Zhan, H., Li, B., Wu, L., Cai, M., Zhang, L., Huang, W., Jin, P., & Liang, H. (2025). Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.. Int J Cancer, 157(8), 1637-1647. https://doi.org/10.1002/ijc.35511

15/10/2025 Lire →

Oligometastatic Gastric Cancer: Novel Considerations for Personalized Approach.

BACKGROUND: Metastatic disease traditionally classifies gastric cancer as stage M1, precluding surgical intervention and enrolling patients in palliative treatment protocols. This principle holds rega…

Thérapies de Conversion

Kyrochristou, G. D., Lianos, G. D., Kyrochristou, I. D., Mitsis, M., & Vlachos, K. (2025). Oligometastatic Gastric Cancer: Novel Considerations for Personalized Approach.. J Gastrointest Cancer, 56(1), 201. https://doi.org/10.1007/s12029-025-01325-6

14/10/2025 Lire →

Superselective transarterial chemoembolization (SSTACE) as second-line conversion therapy for locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma: a preliminary retrospective cohort study.

BACKGROUND: In patients with locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma, conversion therapy has shown suboptimal efficacy, typically resulting in stable disease …

Thérapies de Conversion

Chen, J., Zhang, W., Wang, T., Fu, Y., Qing, Y., Chen, N., Ye, P., Wang, Q., Huang, H., Wei, S., & Lv, Q. (2025). Superselective transarterial chemoembolization (SSTACE) as second-line conversion therapy for locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma: a preliminary retrospective cohort study.. Eur J Med Res, 30(1), 952. https://doi.org/10.1186/s40001-025-03306-8

09/10/2025 Lire →